New hope for lymphoma patients after chemo fails
NCT ID NCT02588651
Summary
This study tested whether the drug brentuximab vedotin could help control T-cell lymphoma that had returned or stopped responding to previous chemotherapy. The trial enrolled 23 patients whose cancer cells had low levels of a specific target called CD30. Researchers wanted to see if this targeted drug could shrink tumors and extend patients' lives even with low target levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
-
Wayne State University, Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.